Tiziana Life Sciences Completes Alzheimer's Trial Dosing
The clinical trial evaluates if intranasal foralumab can reduce neuroinflammation in patients with Alzheimer's disease.
Updated on Oct. 16, 2026 in Alzheimer’s
Live Poll
Should Alzheimer's research prioritize targeting neuroinflammation alongside current amyloid-clearing therapies?
Tiziana Life Sciences has completed the dosing initiation for all participants in a Phase 2 trial testing the efficacy of intranasal foralumab. The study focuses on whether this anti-CD3 monoclonal antibody can address chronic brain inflammation in early or mild Alzheimer's patients.
Why it matters
By targeting activated microglia and neuroinflammation, the trial aims to determine if modulating the immune system can slow disease progression. Researchers are investigating this approach as both a standalone therapy and in combination with existing treatments like lecanemab and donanemab.
The study is a Phase 2 randomized, placebo-controlled trial measuring endpoints through TSPO-PET imaging, cognitive function, and fluid biomarkers. Results are currently unknown as the study proceeds toward its 2027 readout.
The players
Tiziana Life Sciences
This biotechnology company focuses on the discovery and development of novel molecules for the treatment of inflammatory diseases and oncology.
Brigham and Women's Hospital
This is a major teaching hospital of Harvard Medical School that serves as a global leader in clinical research and patient care.
The details
The trial utilizes intranasal foralumab to induce regulatory T cells, which researchers believe will mitigate neuroinflammation in the brain. The study is conducted at the Ann Romney Center at Brigham and Women's Hospital.
Timeline
October 2026: Dosing was completed for all study participants.
Q1 2027: Topline trial data is expected to be released.
The Big Picture
This clinical trial aligns with broader research at the Ann Romney Center for Neurologic Diseases focused on the role of neuroinflammation in brain disorders. The study represents a shift toward immunomodulatory interventions for treating Alzheimer's disease.
While this treatment is currently in the clinical trial phase, the study results may eventually offer new therapeutic options for patients with early or mild Alzheimer's. Participants and their families are currently waiting for the 2027 data to determine the drug's safety and efficacy profile.
The takeaway
This trial highlights a move toward investigating the immune system as a therapeutic target for neurodegenerative conditions. Families and patients should monitor the 2027 data to understand if immunomodulation provides a viable path forward for Alzheimer's care.
What happens next
Topline data from this Phase 2 trial is expected to be published in the first quarter of 2027.
Further reading
Learn more about the latest research and breakthroughs in the field on our Alzheimer’s section.
Live Poll
Should Alzheimer's research prioritize targeting neuroinflammation alongside current amyloid-clearing therapies?
